The estimated Net Worth of Scott Biller is at least $11 Million dollars as of 11 June 2019. Scott Biller owns over 7,218 units of Foghorn Therapeutics stock worth over $312,668 and over the last 11 years Scott sold FHTX stock worth over $10,699,357.
Scott has made over 69 trades of the Foghorn Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Scott exercised 7,218 units of FHTX stock worth $16,890 on 11 June 2019.
The largest trade Scott's ever made was exercising 46,795 units of Foghorn Therapeutics stock on 6 December 2017 worth over $81,423. On average, Scott trades about 6,794 units every 23 days since 2014. As of 11 June 2019 Scott still owns at least 33,729 units of Foghorn Therapeutics stock.
You can see the complete history of Scott Biller stock trades at the bottom of the page.
Scott's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over $262,160 worth of Foghorn Therapeutics stock and bought 305,500 units worth $4,888,000 . The most active insiders traders include Adam Koppel, Ian F Smith, and B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of $663,343. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth $190,000.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: